Entia Biosciences, Inc.
ERGO
$0.00
$0.00-50.00%
OTC PK
| 12/31/2016 | 09/30/2016 | 06/30/2016 | 03/31/2016 | 12/31/2015 | |
|---|---|---|---|---|---|
| Net Income | -1.40M | -1.27M | -1.34M | -2.01M | -2.26M |
| Total Depreciation and Amortization | 17.60K | 21.10K | 23.90K | 27.90K | 32.00K |
| Total Amortization of Deferred Charges | 25.60K | 6.60K | 10.20K | 72.60K | 137.30K |
| Total Other Non-Cash Items | 155.20K | 17.90K | 78.50K | 601.10K | 725.10K |
| Change in Net Operating Assets | 482.20K | 886.00K | 804.20K | 660.60K | 829.00K |
| Cash from Operations | -715.10K | -334.50K | -427.60K | -649.90K | -536.60K |
| Capital Expenditure | -- | 0.00 | -1.70K | -8.10K | -8.10K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -7.10K | -7.60K | -11.30K | -9.70K | -13.20K |
| Cash from Investing | -7.10K | -7.60K | -13.00K | -17.80K | -21.30K |
| Total Debt Issued | 829.40K | 370.00K | 295.00K | 145.00K | 100.00K |
| Total Debt Repaid | -55.20K | -51.00K | -47.10K | -131.60K | -177.70K |
| Issuance of Common Stock | -- | 0.00 | 40.20K | 475.20K | 560.20K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -16.10K | -11.70K | -- | -- |
| Cash from Financing | 774.20K | 302.90K | 276.40K | 488.60K | 482.50K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 52.00K | -39.20K | -164.20K | -179.10K | -75.30K |